414 related articles for article (PubMed ID: 16518429)
1. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate.
Murphy N; Diviney M; Szer J; Bardy P; Grigg A; Hoyt R; King B; Macgregor L; Holdsworth R; McCluskey J; Tait BD
Bone Marrow Transplant; 2006 Apr; 37(8):773-9. PubMed ID: 16518429
[TBL] [Abstract][Full Text] [Related]
2. Methylenetetrahydrofolate reductase C677T genotypes and clinical outcome following hematopoietic cell transplant.
Azarpira N; Ramzi M; Aghdaie MH; Daraie M; Geramizadeh B
Exp Clin Transplant; 2007 Dec; 5(2):693-7. PubMed ID: 18194124
[TBL] [Abstract][Full Text] [Related]
3. The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplants.
Murphy NM; Diviney M; Szer J; Bardy P; Grigg A; Hoyt R; King-Kallimanis B; Holdsworth R; McCluskey J; Tait BD
Biol Blood Marrow Transplant; 2012 May; 18(5):722-30. PubMed ID: 21920473
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of the methylenetetrahydrofolate reductase gene and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.
Kim I; Lee KH; Kim JH; Ra EK; Yoon SS; Hong YC; Park SS; Kim CS; Park S; Kim BK
Ann Hematol; 2007 Jan; 86(1):41-8. PubMed ID: 17028897
[TBL] [Abstract][Full Text] [Related]
5. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia.
Robien K; Bigler J; Yasui Y; Potter JD; Martin P; Storb R; Ulrich CM
Biol Blood Marrow Transplant; 2006 Sep; 12(9):973-80. PubMed ID: 16920564
[TBL] [Abstract][Full Text] [Related]
6. Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia.
Robien K; Ulrich CM; Bigler J; Yasui Y; Gooley T; Bruemmer B; Potter JD; Radich JP
Clin Cancer Res; 2004 Nov; 10(22):7592-8. PubMed ID: 15569990
[TBL] [Abstract][Full Text] [Related]
7. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation.
Elmaagacli AH; Koldehoff M; Landt O; Beelen DW
Bone Marrow Transplant; 2008 May; 41(9):821-6. PubMed ID: 18209723
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S;
Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916
[TBL] [Abstract][Full Text] [Related]
12. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
Viel DO; Tsuneto LT; Sossai CR; Lieber SR; Marques SB; Vigorito AC; Aranha FJ; de Brito Eid KA; Oliveira GB; Miranda EC; de Souza CA; Visentainer JE
Scand J Immunol; 2007 Dec; 66(6):703-10. PubMed ID: 18021367
[TBL] [Abstract][Full Text] [Related]
13. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
14. Functional polymorphism of CTLA-4 and ICOS genes in allogeneic hematopoietic stem cell transplantation.
Wu J; Tang JL; Wu SJ; Lio HY; Yang YC
Clin Chim Acta; 2009 May; 403(1-2):229-33. PubMed ID: 19332044
[TBL] [Abstract][Full Text] [Related]
15. CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Bogunia-Kubik K; Duda D; Suchnicki K; Lange A
Haematologica; 2006 Dec; 91(12):1628-34. PubMed ID: 17145599
[TBL] [Abstract][Full Text] [Related]
16. Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype.
Sugimoto K; Murata M; Onizuka M; Inamoto Y; Terakura S; Kuwatsuka Y; Oba T; Miyamura K; Kodera Y; Naoe T
Int J Hematol; 2008 Jun; 87(5):451-458. PubMed ID: 18365141
[TBL] [Abstract][Full Text] [Related]
17. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
[TBL] [Abstract][Full Text] [Related]
18. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
[TBL] [Abstract][Full Text] [Related]
19. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
20. [Allogeneic hematopoietic stem cell transplantation from HLA one-locus-mismatched related donors].
Hyo R; Taguchi J; Kamijo A; Tanaka M; Hashimoto C; Kanamori H; Motomura S; Maruta A; Ishigatsubo Y
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1845-9. PubMed ID: 19920386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
